Fagron Sa · EURONEXT:FAGR
Fagron Sa — Fagron Sa Ord — Q1 2026 Earnings Presentation
7 slides from Fagron Sa's earnings presentation, Apr 9, 2026
Slide 1: Q1 2026 Trading Update
Q1 2026 Trading Update Rafael Padilla CEO Karin de Jong CFO 9 April 2026
Slide 2: Disclaimer
Disclaimer The contents of this document, including all statements made therein, are based on estimates, assumptions and other information currently available to the management of Fagron. Certain statements in this presentation may be deemed to be forward-looking. Such forward-looking statements are
Slide 3: Solid start to 2026 with all regions delivering organic growth at CER
Solid start to 2026 with all regions delivering organic growth at CER Robust revenue growth driven by outstanding performance in Q1 2026 Latin America and strong contributions from recently acquired companies Organic revenue growth at CER of 3.2% reflects positive Total revenue €263.4m contributions
Slide 4: All regions contributing, with Latin America the standout performer
All regions contributing, with Latin America the standout performer EMEA Latin America NA – PAC +14.7% +34.8% -2.8% 31.4 1.1 28.6 14.9 1.0 20.1 13.7 80.4 75.6 +2.8% 15.2 +10.4% +0.6% Org. growth Org. growth Org. growth CER CER CER 45.5 54.5 36.1 26.3 5.3 5.9 22.7 23.8 Q1 2025 Q1 2026 Q1 2025 Q1 2026
Slide 5: On track to deliver mid- to high-single digit organic growth at CER
On track to deliver mid- to high-single digit organic growth at CER Revenue REBITDA Capex margin Mid- to high-single c.20% ~3.5% digit organic (H2 > H1) of revenue1 growth at CER 1 Excludes one-off projects 5
Slide 6: Together we create the future of personalized medicine
The global leader in pharmaceutical compounding Together we create the future of personalized medicine Defensive Business Strong Cash Operational Model Generation Excellence Disciplined Sustainability Unique Market M&A Focus Positioning 6
Slide 7: Questions
Questions 7